Cargando…

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)

OBJECTIVE: To compare the effect of sitagliptin (100 mg) vs glimepiride (1–3 mg) as add-on therapy in Indian type 2 diabetes (T2DM) patients on treatment with insulin and metformin (SWIM study). RESEARCH DESIGN AND METHODS: This 24-week, controlled, open-label study randomized T2DM patients (n = 440...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kesavadev, Jothydev, Pillai, Pradeep Babu Sadasivan, Shankar, Arun, Krishnan, Gopika, Jothydev, Sunitha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670271/ https://www.ncbi.nlm.nih.gov/pubmed/28982699 http://dx.doi.org/10.1530/EC-17-0100

Ejemplares similares

Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting
por: Kesavadev, Jothydev, et al.
Publicado: (2012)

Telemedicine for diabetes care: An Indian perspective - feasibility and efficacy
por: Kesavadev, Jothydev, et al.
Publicado: (2015)

Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System
por: Kesavadev, Jothydev, et al.
Publicado: (2023)

Digital health and diabetes: experience from India
por: Kesavadev, Jothydev, et al.
Publicado: (2021)

Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas
por: Kesavadev, Jothydev, et al.
Publicado: (2020)

Management Strategies for Dealing With Surges of the COVID-19 Pandemic
por: Raveendran, A.V., et al.
Publicado: (2021)

Time-in-range as a target in type 2 diabetes: An urgent need
por: Saboo, Banshi, et al.
Publicado: (2021)

Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era
por: Shrivastava, Abhishek, et al.
Publicado: (2023)

The Do-It-Yourself Artificial Pancreas: A Comprehensive Review
por: Kesavadev, Jothydev, et al.
Publicado: (2020)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A(1)chieve study
por: Kesavadev, Jothydev
Publicado: (2013)

IDF21-0236 Prevalence of Breakthrough Covid Infections and Its Severity among Vaccinated Individuals
por: Kesavadev, J., et al.
Publicado: (2022)

A new interventional home care model for COVID management: Virtual Covid IP
por: Kesavadev, Jothydev, et al.
Publicado: (2021)

Human Digital Twin for Personalized Elderly Type 2 Diabetes Management
por: Thamotharan, Padmapritha, et al.
Publicado: (2023)

Reducing the Cost of Diabetes Care with Telemedicine, Smartphone, and Home Monitoring
por: Kesavadev, Jothydev, et al.
Publicado: (2023)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Suggested use of vaccines in diabetes
por: Kesavadev, Jothydev, et al.
Publicado: (2012)

Modulation of Adipocytokines Production and Serum NEFA Level by Metformin, Glimepiride, and Sitagliptin in HFD/STZ Diabetic Rats
por: Saad, Mohamed I., et al.
Publicado: (2015)

Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers
por: Jung, Sang-hoon, et al.
Publicado: (2014)

Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2018)

IDF21-0234 The Virtual COVID In-patient (VCIP) Care and Post Covid Symptoms: a Comparison with Conventional Care
por: Kesavadev, J., et al.
Publicado: (2022)

Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects
por: Ju, Gehang, et al.
Publicado: (2020)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Effects of Evogliptin as Add on in Type 2 Diabetes (T2DM) Subjects Inadequately Controlled With Metformin and Glimepiride Combination
por: Guha, Shaibal
Publicado: (2021)

Evolving Scope of Clinical Empathy in the Current Era of Medical Practice
por: B, Jayakrishnan, et al.
Publicado: (2023)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
por: Kousoulakou, Hara, et al.
Publicado: (2017)

Unproven Therapies for Diabetes and Their Implications
por: Kesavadev, Jothydev, et al.
Publicado: (2016)

Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
por: Park, Cheol-Young, et al.
Publicado: (2014)

Low dose Mifepristone (100 mg) for medical termination of pregnancy
por: Seth, Shikha, et al.
Publicado: (2011)

Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study
por: Devarajan, T. V., et al.
Publicado: (2017)

Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double‐blind, non‐inferiority trial
por: Kim, Yonghyun, et al.
Publicado: (2018)

Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
por: Gudipaty, Lalitha, et al.
Publicado: (2014)

Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes
por: Ishii, Hiroaki, et al.
Publicado: (2014)

Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients
por: Hussain, Mazhar, et al.
Publicado: (2019)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

Steroid use during COVID-19 infection and hyperglycemia – What a physician should know
por: Sosale, Aravind, et al.
Publicado: (2021)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine
por: Dahlöf, Carl, et al.
Publicado: (2004)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
por: Kim, Hyun Min, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9s7uebvcj0scg6bptmo2r7a2b8